Equivalence of ELISpot assays demonstrated between major HIV network laboratories.

Publication Type:

Journal Article

Source:

PloS one, Volume 5, Issue 12, p.e14330 (2010)

Keywords:

2010, Center-Authored Paper, Vaccine and Infectious Disease Division

Abstract:

The Comprehensive T Cell Vaccine Immune Monitoring Consortium (CTC-VIMC) was created to provide standardized immunogenicity monitoring services for HIV vaccine trials. The ex vivo interferon-gamma (IFN-γ) ELISpot is used extensively as a primary immunogenicity assay to assess T cell-based vaccine candidates in trials for infectious diseases and cancer. Two independent, GCLP-accredited central laboratories of CTC-VIMC routinely use their own standard operating procedures (SOPs) for ELISpot within two major networks of HIV vaccine trials. Studies are imperatively needed to assess the comparability of ELISpot measurements across laboratories to benefit optimal advancement of vaccine candidates.